Clinical Trials Logo

Nasopharyngeal Cancer clinical trials

View clinical trials related to Nasopharyngeal Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03682055 Terminated - Clinical trials for Nasopharyngeal Carcinoma

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Start date: April 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.

NCT ID: NCT03144661 Terminated - Ovarian Cancer Clinical Trials

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Start date: May 25, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.

NCT ID: NCT02875613 Terminated - Clinical trials for Nasopharyngeal Cancer

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

Start date: January 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether avelumab, an investigational antibody against programmed death-ligand (PD-L1), has an effect on recurrent nasopharyngeal cancer. Avelumab is designed to block the interaction between programmed cell death protein 1 (PD-1), a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer.

NCT ID: NCT02080416 Terminated - Gastric Cancer Clinical Trials

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Start date: July 2014
Phase: Phase 0
Study type: Interventional

The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.